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Abstract
Background: The propensity for off-target activity of Streptococcus pyogenes Cas9 (SpCas9) has been considerably
decreased by rationally engineered variants with increased fidelity (eSpCas9; SpCas9-HF1). However, a subset of
targets still generate considerable off-target effects. To deal specifically with these targets, we generated new
“Highly enhanced Fidelity” nuclease variants (HeFSpCas9s) containing mutations from both eSpCas9 and
SpCas9-HF1 and examined these improved nuclease variants side by side to decipher the factors that affect
their specificities and to determine the optimal nuclease for applications sensitive to off-target effects.
Results: These three increased-fidelity nucleases can routinely be used only with perfectly matching 20-nucleotide-long
spacers, a matching 5′ G extension being more detrimental to their activities than a mismatching one. HeFSpCas9
exhibit substantially improved specificity for those targets for which eSpCas9 and SpCas9-HF1 have higher off-target
propensity. The targets can also be ranked by their cleavability and off-target effects manifested by the increased fidelity
nucleases. Furthermore, we show that the mutations in these variants may diminish the cleavage, but not the
DNA-binding, of SpCas9s.
Conclusions: No single nuclease variant shows generally superior fidelity; instead, for highest specificity cleavage,
each target needs to be matched with an appropriate high-fidelity nuclease. We provide here a framework for
generating new nuclease variants for targets that currently have no matching optimal nuclease, and offer a simple
means for identifying the optimal nuclease for targets in the absence of accurate target-ranking prediction tools.
Keywords: CRISPR, Cas9, eSpCas9, SpCas9-HF1, HeFSpCas9, HeFm2SpCas9, High fidelity nuclease, sgRNA, Disruption
assay, Off-target, Truncated sgRNA, Extended sgRNA
Background
Cas9 proteins are RNA-guided endonucleases that can
be directed to cleave a chosen DNA sequence [1–4].
This process requires complementarity between the
Cas9-associated single guide RNA (sgRNA) and the target
site in addition to the presence of a short protospacer-
adjacent motif (PAM) at the 3′ end of the target [5–13].
Although it has been demonstrated that the Streptococcus
pyogenes Cas9 (SpCas9) nuclease can be used for genome
engineering, its widespread use has been limited by its off-
target activity; i.e., the nuclease also cleaves targets that
show limited, imperfect complementarities with the associ-
ated sgRNA [14–21]. The off-target sequences are difficult
to predict and have been shown to contain mismatches in
up to 5 or 6 positions [15, 22, 23], a property that may
interfere with many research applications as well as thera-
peutic uses. Much effort has been devoted to circumvent
these confounding effects of the nuclease, such as reducing
the amount of active Cas9 in the cell [14, 24, 25], using
truncated sgRNAs that bear shortened regions of target
site complementarity [23], engineering SpCas9 mutants
[26], using paired SpCas9 nickases [27, 28], or using pairs
of catalytically inactive SpCas9 fused to a non-specific FokI
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nuclease domain [29–31]. Recently, attempts to use
structure-guided engineering of SpCas9 to reduce its off-
target activities have been reported: the enhanced SpCas9
[eSpCas9(1.1), K848A/K1003A/R1060A] [32], hereinafter
referred to as eSpCas9, was developed to decrease the af-
finity of the protein for the non-target DNA strand, hence
increasing the strand’s propensity for reinvading the RNA–
DNA hybrid helix and, therefore, decreasing the stability of
mismatch-containing helices. By contrast, mutations con-
tained in the high fidelity Cas9 (SpCas9-HF1, N497A/
R661A/Q695A/Q926A) [33] that weaken the interactions
of the protein with the target DNA strand are aimed at de-
creasing the energetics of the SpCas9–sgRNA complex so
that it retains a robust on-target activity but has a dimin-
ished ability to cleave mismatched off-target sites. Both
mutants exhibited considerably reduced off-target effects
when assessed by unbiased whole-genome off-target ana-
lysis: their cleavage activities toward off-targets with
multiple mismatches were almost completely eliminated,
although some off-targets, mainly with single-base mis-
matches, were found. However, a subset of targets, referred
to as atypical, with repetitive or homopolymeric sequences
were still cleaved with considerable off-target effects [33].
While these results are very encouraging, it is difficult to
decide which SpCas9 variant is superior for applications
where the avoidance of off-target activity is of paramount
interest because they were characterized in differing ex-
perimental setups that exploited different sets of targets in
different (either U2OS or HEK) cells and employed differ-
ent methods (GUIDE-seq [18] versus BLESS [34]) to assess
their genome-wide specificity.
Here, we generate new variants (“Highly enhanced
Fidelity” or HeFSpCas9s) of SpCas9, containing combi-
nations of mutations from both eSpCas9 and SpCas9-
HF1, that show higher fidelity specifically with respect to
those targets for which eSpCas9 and SpCas9-HF1 exhibit
a higher off-target propensity. Furthermore, we directly
compare these highly improved nucleases in the same
system to understand the factors that affect their specifi-
city and to help select for which off-target-sensitive ap-
plications each would be most suitable.
Results
In order to facilitate a thorough comparison of the nu-
clease variants, we subcloned the wild-type and mutant
nucleases (eSpCas9, SpCas9-HF1 and the mutants devel-
oped in this study, HeFSpCas9 and later HeFm1- and
HeFm2SpCas9) into the same plasmid backbone and tai-
lored them to have identical NLS and FLAG tags at their
termini (Fig. 1).
To assess the activity of the Highly enhanced Fidelity
SpCas9 nuclease (HeFSpCas9) we performed direct
comparisons with eSpCas9, SpCas9-HF1, and the wild
type (WT) SpCas9 on a large number of on-target sites.
Testing 16 genomic targets in N2a cells, we measured ei-
ther the on-target HR-mediated integration of a GFP cas-
sette with 1000-bp-long homology arms [35] (Additional
file 1: Figure S1a) or the indel frequencies by Tracking of
Indels by DEcomposition (TIDE) [36] on five genomic loci
(Pten, Prnp, Rbl2, Ttn, and Tp53) (Additional file 1:
Figure S1b). To our surprise, the increased fidelity nu-
clease variants performed poorly in these assays in con-
trast to those reported earlier [32, 33]. A closer
inspection of the results revealed that many of these
targets had been targeted by 21-nucleotide-long spacers
bearing a guanine (G) extension at the start. This is a
commonly applied modification to comply with the
preference for a G nucleotide as the transcription initi-
ation site for the human U6 promoter [37] that is used for
the sgRNAs here and which is the most commonly used
promoter for mammalian sgRNA expression vectors [8].
5′ Extended sgRNAs diminish the activities of improved
fidelity nucleases more with a matching than with a
mismatching G nucleotide
The broad applicability of these nucleases depends on
how they are able to utilize modified sgRNAs. The need
to accept modified sgRNAs is most common because a
U6 promoter is used for sgRNA expression, which re-
quires a starting G nucleotide for efficient transcription.
According to whether the target requires a G at that
position, different practices exist for modifying the 5′
end of the spacer of the sgRNA to meet the starting G
requirement. We systematically examined the compati-
bility of routinely implemented modifications of 5′ ends
of the spacers with the SpCas9 variants. In these experi-
ments, we examined 100 sgRNAs using an EGFP disrup-
tion assay (Additional file 1: Figure S1c–e) in N2a.EGFP
cells [15, 38]. The 20-nucleotide spacers to be examined,
unless otherwise noted, start with a 5′ end G nucleotide
to facilitate specifically investigating the effect under
scrutiny. First we examined the effect of appending ei-
ther (i) a 21st 5′ end non-matching (Fig. 2a; Additional
file 1: Figure S2a, c) or (ii) a matching G nucleotide
(Fig. 2b; Additional file 1: Figure S2b, S2d) to the spacer
sequence on the activities of the increased fidelity nucle-
ases. We compared this activity to that of the WT and
to the corresponding unmodified guides (with 20-
nucleotide-long spacer). The results of these experi-
ments (Fig. 2a, b) demonstrate that 21-nucleotide-long
spacers interfere with the activities of the increased fidelity
nucleases, providing an explanation for the effects previ-
ously seen in Additional file 1: Figure S1a, b. Interestingly,
extending the guide with a matching 5′ end G nucleotide
is much more detrimental to the activities of these nucle-
ase variants than extending it with a mismatching one. In
further experiments, we systematically examined and
showed, confirming also earlier reports [32, 33], that the
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routine application of the increased fidelity nucleases is
not compatible with modified sgRNAs that are generated
by commonly applied approaches such as (i) altering the
non-G 5′ end nucleotide to a G, (ii) using the spacers
without alteration, i.e., with the 5′ end non-G nucleotide,
or (iii) truncating back the guide until a G nucleotide is
encountered, resulting in spacers between 19 and 17 nu-
cleotides in length (Additional file 1: Figure S2e, f ). All of
these alterations, however, diminish the activities of all
mutant nucleases to different extents; eSpCas9 showed
lower sensitivity compared to SpCas9-HF1. These results
indicate that enhanced and high-fidelity nucleases are gen-
erally not compatible with these approaches and can be
used only with matching 20-nucleotide-long spacers. This
finding is critical for their effective application and
methods that relax the restriction for a 5′ end G nucleo-
tide imposed by employing the U6 promoter for sgRNA
expression might prove to be very valuable tools for these
nucleases [39–43] (see Additional file 1: Supplementary
results 1 for detailed information).
Ranking by activity and target discrimination/selectivity
of improved fidelity nuclease variants
Based on the above results, we performed direct compari-
sons of HeFSpCas9 with eSpCas9, SpCas9-HF1, and the
WT SpCas9, employing 24 sgRNAs with 20-nucleotide-
long spacers using EGFP disruption assay. Both eSp-
Cas9 and SpCas9-HF1 demonstrate high activities
Fig. 2 Extending the guide RNA with a matching 5′ end G nucleotide is much more detrimental their activities than extending with a mismatching
one in the case of eSpCas9 and SpCas9-HF1. Effect of 5′ extension of the sgRNA with a a mismatching G or b a matching G nucleotide on the activities
of SpCas9 nucleases in comparison with using perfectly matching 20-nucleotide-long spacers (data used are from Additional file 1: Figure S2a, c and
S2b, d; sites targeted are provided in Additional file 2). Schematics for the spacers used are depicted below the categories as green combs and the 21st
G nucleotide extensions are depicted as a red bent end tooth if mismatching; lower case g represents appended nucleotides; numbering corresponds
to the distance from the PAM. Tukey-type notched boxplots by BoxPlotR [67]: center lines show the medians; box limits indicate the 25th and 75th
percentiles; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles; notches indicate the 95% confidence intervals for
medians; crosses represent sample means; data points are plotted as open circles and correspond to the different targets tested (in total 26 and 10,
respectively, for a and b). Each pair of means is statistically different at the p < 0.05 level: a SpCas9–eSpCas9 (<0.001), SpCas9–SpCas9-HF1 (<0.001),
SpCas9-HF1–eSpCas9 (<0.015); b statistically different pairs SpCas9–eSpCas9 (<0.001), SpCas9–SpCas9-HF1 (<0.001)
Fig. 1 SpCas9 variants employed in these studies. Schematics depicting the main features of the wild type and the five mutant variants of
SpCas9 used: each protein sequence is flanked by a nuclear localization signal (NLS) at both ends and is preceded by a 3xFLAG tag. HeF-variants
containing combinations of mutations from both eSpCas9 and SpCas9-HF1
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(Fig. 3a; Additional file 1: Figure S1f ), showing > 80%
activity for more than 83% and 41% of these 24 targets,
respectively, when compared to the WT SpCas9
(Fig. 3b). HeFSpCas9 shows activity only on a subset of
these targets. Interestingly, although these nucleases
show decreased overall activity, they are capable of un-
diminished activity, comparable to that of WT SpCas9
on particular individual targets. eSpCas9 is the least
discriminative and HeFSpCas9 the most discriminative
in target selection in this respect.
Fidelity ranking among the mutant SpCas9 nuclease
variants
We also aimed to compare the fidelity of these nucle-
ases. Unbiased genome-wide off-target analyses are re-
ported to barely detect off-targets in case of “typical
sequences” [33] cleaved by eSpCas9 and SpCas9-HF1
[32, 33], making this approach less appropriate for com-
parative analysis of the nucleases. Thus, we decided to
compare the effect of single base mismatches on their
fidelity in an EGFP disruption assay. This assay is a sen-
sitive surrogate for the off-target activity of Cas9 nucle-
ases [15, 38]. We placed mismatches in the PAM distal
regions (between positions 19 and 14) of the spacer
sequence, where mismatches are most tolerated by
SpCas9. Here, 16 targets were examined employing 144
mismatching sgRNAs; each target with a matching and
nine one-base mismatching sgRNAs (three possible mis-
matches for each of the three positions; Fig. 4a). Since
we found that mixing the three possible sgRNAs mis-
matched at the same position resulted in sensitive
reporting of the off-target activities by the disruption
assay (Additional file 1: Figure S3a), we used this ap-
proach here.
These results show that there is a big difference in fi-
delity between WT SpCas9 and eSpCas9 or SpCas9-
HF1. Whereas WT SpCas9 barely distinguishes perfect
matches from mismatches for the majority of the targets
Fig. 3 Side-by-side comparison of SpCas9 variants programmed with perfectly matching sgRNAs reveal a target-selectivity ranking among the
variants in the order of eSpCas9 > SpCas9-HF1 > HeFSpCas9. a EGFP disruption activities of the nucleases, calculated as described in “Methods”.
Bars correspond to averages of n = 3 parallel samples; error bars represent the standard errors estimated by Gaussian error propagation of the
component standard deviations associated with both EGFP and mCherry (transfection control) values. The target numbers in squares are the 16
targets examined in Fig. 4a. b Summary of the characteristics of distributions of data for on-target disruption activities of nuclease variants normalized to
that of the WT SpCas9. Tukey-type notched boxplots by BoxPlotR: center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers
extend 1.5 times the interquartile range from the 25th and 75th percentiles; notches indicate the 95% confidence intervals for medians; crosses represent
sample means; data points are plotted as open circles. The sample points (24 in case of each variant) correspond to the targets present on Fig. 3a. Each pair
of means is statistically different at the p< 0.05 level: SpCas9-HF1–eSpCas9 (<0.002), SpCas9-HF1–HeFSpCas9 (<0.001), HeFSpCas9–eSpCas9 (<0.001)
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Fig. 4 Cleavability ranking of the targets by nuclease variant as well as fidelity ranking (eSpCas9 < SpCas9-HF1 < HeFSpCas9) of the nucleases on these
targets is apparent. Disruption and indel formation activities of SpCas9 nucleases programmed with perfectly matching or partially mismatching sgRNAs.
a Heat maps showing the relative activities (white to green) of the nuclease variants compared to the WT for each of the targets and the ratios of
off-target to on-target disruption activities (blue to white) of the WT and mutant nucleases measured employing the indicated target and mismatching
spacer sequences; grey and black boxes indicate not determined due to diminished on-target activities and sample loss, respectively. b–d Specificities
(on-target:off-target ratio) of the nucleases assessed by b disruption activities, c deep-sequencing on indel formation (eSpCas9 and SpCas9-HF1) and
disruption activities (SpCas9), and d deep-sequencing on indel formation (HeFSpCas9) and disruption activities (SpCas9, eSpCas9, SpCas9-HF1)
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examined, eSpCas9 and SpCas9-HF1 are capable of strong
discrimination (Fig. 4; Additional file 1: Figure S3b). eSp-
Cas9 does not exhibit any detectable cleavage (< 3%) with
20 out of 48 mismatch positions of sgRNAs, whereas
SpCas9-HF1 shows no cleavage with 28 out of 47. These
confirm earlier reports that eSpCas9 and SpCas9-HF1
have greatly increased target fidelity not only when
presented with multiple- but also with single-base mis-
matched sequences. Our results also reveal that SpCas9-
HF1 possesses higher fidelity, exhibiting less off-target
cleavage than eSpCas9. The number of spacers with mis-
matching positions that result in higher than 80% of the
corresponding disruption levels found with the matching
spacers are: 42 for the WT protein, 18 for eSpCas9, and
only three for SpCas9-HF1 (Additional file 1: Figure S3b).
Interestingly, for some targets (targets 1, 3, 4, and 5 in
Fig. 4a) even SpCas9-HF1 shows higher off-target effects,
although the difference between the sequence characteris-
tics of these targets with low and high off-target cleavage
is not apparent. Importantly, HeFSpCas9 exhibits high-
fidelity activity particularly on these targets (Fig. 4a).
Since several off-target positions resulted in disruption
levels at around or under the detection limit of the
assay, we performed deep sequencing on 67 samples to
assess more precisely their respective fidelity on single-
base mismatched sequences (for details of the read num-
bers see Additional file 2: Deepseq reads). SpCas9-HF1
also proved to be a higher fidelity nuclease than eSpCas9
by deep sequencing, showing considerably lower off-
target cleavage (greater than twofold) with 7 out of 14
mismatch-position containing guide RNAs (Fig. 4c).
When examining those targets by deep sequencing (tar-
gets 1, 3, 4, and 5) for which eSpCas9 and SpCas9-HF1
failed to achieve high fidelity, HeFSpCas9 showed de-
tectable off-target activity only with 4 out of 12 mis-
matching positions, with the rest exhibiting off-target
activity indistinguishable from the background. These
results demonstrate a spectacularly increased specificity
of HeFSpCas9 on these targets of about 50- to 400-fold
over the two other increased fidelity nucleases (Fig. 4d).
Thus, the rank of the nucleases is, in order of increasing
fidelity, eSpCas9 < SpCas9-HF1 < HeFSpCas9.
Ranking among the targets
Applying the four nucleases to a number of targets and
exploiting a great number of sgRNAs with mismatching
guides (Fig. 4a) revealed another important feature: a
ranking among the targets due to differences in the effi-
ciency with which targets are cleaved. Targets efficiently
cleaved by a nuclease with both perfectly matching and
mismatching guides were likely to be cleaved efficiently
by another higher fidelity nuclease with perfectly matching
sgRNAs but not (or much less) with mismatching ones. In
this way targets could be ranked according to their
requirements for a type of nuclease to result in optimal
(efficient with minimal off-targets), high specificity cleav-
age. In this ranking, at one end are those targets that are
efficiently cleaved by all three nuclease variants; however,
only the highest fidelity HeFSpCas9 cleaves them with lit-
tle to no off-target effect. Such targets are, e.g., 1, 3, 4, and
5 in Figs. 3 and 4. On this kind of target both eSpCas9
and SpCas9-HF1 showed significant off-target activities
with single-base mismatched guides: in particular they
showed, on average, 93 and 60% of the corresponding on-
target activities, respectively, while for the rest of the tar-
gets (12/16) these off-target activities were only 26 and
6%, respectively (calculated from the data shown in Fig. 4).
By contrast, at the other end of the ranks are those targets
that are cleaved by eSpCas9 with > 80% efficiency of WT
SpCas9 (such as targets 8 and 24 in Fig. 4a) and without
much off-target activity (note that for such targets
even the WT protein has decreased off-target activity).
Although the difference in terms of fidelity and target
selectivity is much larger between SpCas9-HF1 and
HeFSpCas9, target ranking is also clearly discernible
between eSpCas9 and SpCas9-HF1, targets 2, 9, 14,
and 16 being efficiently and much more accurately tar-
geted by SpCas9-HF1.
To confirm that these results are not specific only for
the mouse cell line used, we selected nine targets of vari-
ous ranks (covering optimal sequences for each of the
variants, e-, -HF1, or HeFSpCas9 and used previously in
the experiment in Fig. 4a) and repeated the same experi-
ment in human cells (HEK-293) using a cell line con-
taining a single-copy integrated EGFP (HEK-293.EGFP),
similar to the N2a.EGFP cells used. To each target site
nine single-base mismatched guides were applied, thus
using altogether 81 mismatching guides. The patterns re-
vealed by these experiments on the nucleases (Additional
file 1: Figure S4) are almost identical to those found
previously (shown on Fig. 4a), supporting the idea that the
characteristics of the increased fidelity nucleases and that
of the targets, which have become apparent in this study,
are intrinsic and are not specific to the particular cell line
used in the experiments. The new observation about tar-
get ranking reported here is a key aspect of selecting the
optimal variant for a particular target.
Since off-target effects are also dependent on the
amount of the active nuclease present, we have also
compared the activities as a function of the expression
levels of these nucleases while making considerable ef-
forts to match the expression levels of the variants as
closely as we could (see Additional file 1: Figures S5 and
S6 and Supplementary results 2 for more details). These
experiments revealed that the relative efficiencies and
specificities of these nuclease variants seen in these
studies, particularly the differences between eSpCas9
and SpCas9-HF1, are primarily determined by their
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intrinsic characteristics; however, it cannot be ruled out
that there might also be a contribution to the lower on-
target activities and higher fidelity of SpCas9-HF1 seen
here from its somewhat lower expression levels from
these vectors.
From the observed target ranking it should follow that
the higher the cleavage activity of a nuclease with one
mismatching position-bearing spacer on a target, the
higher is its activity with any other type of modified/im-
perfectly matching (extended, truncated, or with another
mismatching position) guide on the same target, if they
act using the same mechanism. Such a correlation is dis-
cernible from experiments employing sgRNAs with mis-
matching and extended spacers on the same set of
targets (Fig. 4a; Additional file 1: Figure S2a, c). Correl-
ation matrix analysis of the activity data shows positive
Pearson correlations (0.83 or 0.78) that are significant
between the disruption activities of either eSpCas9 or
SpCas9-HF1 programmed with sgRNAs bearing single
mismatching nucleotides and those being extended
with a 5′ end mismatching G targeting the same site
(Additional file 1: Figure S7a, c). In addition, differing
positions of mismatches for the same targets also
showed significant positive correlation (between 0.73
and 0.93 and 0.73 and 0.97 for eSpCas9 and SpCas9-
HF1, respectively; Additional file 1: Figure S7b, d). This
result further supports the idea of target ranking but
also implies that a similar mechanism determines how
these imperfectly matched or modified guides affect the
cleavage activities of SpCas9 nucleases.
To confirm the observed nuclease and target ranking,
an additional 26 spacers were screened for on-target
cleavage activity in the EGFP disruption assay. eSpCas9
and SpCas9-HF1 demonstrate decreased activity on
some of these targets compared to the WT protein to an
extent comparable to that found previously (Additional
file 1: Figure S8a, b). Importantly, while HeFSpCas9
shows no detectable activity on 22 out of 26 targets, it
shows about 80% of the WT activity on two targets
(EGFP sites 26 and 43). To test the fidelity of SpCas9-
HF1 and HeFSpCas9 when dealing with these two
targets, nine one-base mismatching sgRNAs were ap-
plied in case of both. In line with expectations, SpCas9-
HF1 cleaves these targets with non-perfectly matching
sgRNAs (Additional file 1: Figure S8c). By contrast,
HeFSpCas9 demonstrated considerably less off-target ac-
tivity in these experiments.
Generation of a new variant with in-between activity and
fidelity
For the majority of the targets examined here one could
choose from these high fidelity nucleases one that attains
at least 70% disruption activity compared to the WT
protein, combined with a minimal off-target activity on
single-base mismatches (Figs. 3 and 4). However, there
are a few targets on which even the higher fidelity
SpCas9-HF1 showed considerable off-target activity but
that were not yet effectively cleaved by HeFSpCas9.
Based on the ranking of the nuclease variants and tar-
gets established here, we proposed that a variant with
on-target and off-target activity in between that of the
two nucleases (HeFSpCas9 and SpCas9-HF1) could be
generated by reverting single mutations out of the seven
in HeFSpCas9. Based on the results of the former stud-
ies [32, 33] we conjectured that an HeFSpCas9 derivative
lacking either the N497A mutation of SpCas9-HF1
(HeFm1SpCas9) or the K1003A mutation of eSpCas9
(HeFm2SpCas9) would perform better on these targets
and generated these mutants. We selected 17 targets
where SpCas9-HF1 showed either off-target cleavage in
the disruption assay as shown in Fig. 4a (at least with
one mismatched position) or showed higher on-target
activity as shown in Additional file 1: Figure S8. We
tested these targets with the five nucleases, WT-, -HF1,
HeF-, HeFm1-, and HeFm2SpCas9. The results obtained
suggest that HeFm1SpCas9 is quite similar to HeFSp-
Cas9, whereas HeFm2SpCas9 demonstrated on-target
and off-target activities that are more in between the ac-
tivities of SpCas9-HF1 and HeFSpCas9, showing higher
on-target activities (for 11 out of 17 targets; Fig. 5a;
Additional file 1: Figure S9a, b) but also slightly higher
off-target activities (for two out of five targets;
Additional file 1: Figure S9c) than HeFSpCas9. Com-
pared to SpCas9-HF1, HeFm2SpCas9’s specificity is
higher (Fig. 5b) for those five targets on which it dem-
onstrated more than 60% of the activity of the WT
protein (Fig. 5a). Thus, we successfully generated a
nuclease (HeFm2SpCas9) with fidelity and target se-
lectivity in between SpCas9-HF1 and HeFSpCas9.
These data suggested that HeFm2SpCas9 might be worth
a more thorough characterization and, accordingly, we
also included these two new mutants (HeFm1- and
HeFm2SpCas9) in the subsequent experiment.
Kleinstiver and coworkers showed that SpCas9-HF1
efficiently cleaves the off-target site 1 of FANCF site 2
that bears a mismatch close to the PAM region [33]. We
expected that such types of target are a better match for
the higher fidelity HeF nuclease variants and tested the
nucleases on this target by measuring on-target and off-
target indel generation through TIDE [36]. All HeF vari-
ants showed only background-level cleavage activity at
the off-target site, whereas there were differences in on-
target activity; among them the activity of HeFm2SpCas9
was the highest and comparable to that of the WT
(Fig. 5c). This supports our conjecture that HeFm2Sp-
Cas9 might be a good candidate to fill the gap between
SpCas9-HF1 and HeFSpCas9 and demonstrates the rele-
vance of our approach.
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Binding of these nuclease variants to inefficiently cleaved
target DNAs is apparently not diminished compared to
the WT nuclease
Another application of SpCas9, besides being a
programmable nuclease, is using its inactive variant
for delivering effector domains precisely to a chosen
locus within the genome [28, 44–51]. Even active
SpCas9 can be exploited for sequence-specific binding
without target cleavage by complexing it with truncated
sgRNAs harboring 14–15-nucleotide-long spacer se-
quences [52, 53]. The study presented on Additional file 1:
Figure S2f reveals that increased fidelity nucleases exhibit
no cleavage activity when employing truncated sgRNAs
missing more than two nucleotides. We wondered if
these high fidelity nucleases (eSpCas9, SpCas9-HF1,
and HeFSpCas9) can also be exploited for transcrip-
tional activation. For this reason, we compared their
efficiency using five 14-nucleotide-long spacers with an
extra non-matching G in their 5′ end positions,
targeting the promoter region of the Prnp gene that
drives the expression of an EGFP cassette in the
N2a.EGFP cell line. Contrary to the above expectations,
all four nucleases demonstrated comparable activities,
resulting in a 15–20-fold activation (Fig. 6a), which is
similar to that of the catalytically inactive WT and mu-
tant variants (dead eSpCas9, dead SpCas9-HF1, and
dead HeFSpCas9) with the same sgRNA but with 21-
nucleotide-long spacers (four out of five with a
mismatching 5′ G) (Fig. 6b). These results, although in-
direct, suggest that the binding of the nucleases to their
targets is not impaired with altered sgRNAs.
Employing a more direct in vitro approach, we per-
formed polyacrylamide-gel electrophoretic mobility shift
assay of the cleaved target DNAs by the nucleases,
Fig. 5 Variant HeFm2SpCas9 exhibits target selectivity and fidelity between those of SpCas9-HF1 and HeFSpCas9. Disruption and indel formation
activities of SpCas9 nuclease variants bearing combinations of eSpCas9 and SpCas9-HF1 mutations. a Tukey-type notched boxplots of ratios of
on-target disruption activities of the variants to those of WT nucleases as indicated (data used are from Additional file 1: Figure S9a, b; sites targeted are
provided in Additional file 2): center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the interquartile
range from the 25th and 75th percentiles; notches indicate the 95% confidence intervals for medians; crosses represent sample means; data points are
plotted as open circles (17 in case of each variant) and correspond to the targets tested. Statistically different pairs of means at the p < 0.05 level:
SpCas9HF1–HeFm1SpCas9 (<0.001), SpCas9HF1–HeFm2SpCas9 (<0.015), SpCas9HF1–HeFSpCas9 (<0.001). b Comparison of specificities of SpCas9-HF1
and HeFm2SpCas9 assessed in disruption assays with partially mismatching sgRNAs on targets where HeFm2SpCas9 reached at least 60% activity of
the WT protein as in a. c Left panel: mean percentage modifications by WT SpCas9 and variants at FANCF site 2 as well as off-target site 1 from Fig. 5 in
[33], which is readily cleaved by SpCas9-HF1. Percentage modifications were determined by TIDE; error bars represent standard deviation with Gaussian
error propagation for n = 3 parallels. Right panel: specificity of WT and mutant variants on the FANCF site 2 plotted as ratio of on-target to off-target
activity (calculated from the left panel)
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exploiting three targets that were shown to be cleaved
efficiently by WT SpCas9 but not by HeFSpCas9. By
these experiments, we confirmed that although HeF
nucleases do not show nuclease activity, they retain
most of their DNA-binding abilities to these targets
(Additional file 1: Figure S10). Furthermore, to under-
stand the effect of appending an extra G nucleotide to
the 5′ end of the guides, we examined the in vitro binding
of eSpCas9 and SpCas9-HF1 charged with 21-nucleotide-
long sgRNAs to selected targets that were only cleaved
when the 20-nucleotide-long spacers were applied in the
disruption assay (Fig. 2). We found that although the
matching G extension fully diminishes the cleavage
activities of these variants on these targets, their binding
seems to remain unaffected (Additional file 1: Figure S10).
Discussion
In principle, there are two types of approaches that have
been successfully used to decrease off-target cleavage
activities of SpCas9. On the one hand, the length of the
target sequence necessary to elicit double strand cleav-
age may be increased by employing dCas9-FokI [29, 30,
31] or nickases [27, 28]. On the other hand, lessening
the promiscuity of SpCas9 can be achieved by lowering
its activity on off-target sequences while maintaining
reasonably effective on-target activities. This is
attempted by minimizing the exposure of the DNA to
SpCas9 activity by limiting the time of its expression [24,
25, 54–57] or decreasing the level of protein [58, 59],
employing modified sgRNAs (truncated [23] or 5′ ex-
tended with a GG dinucleotide [21]) or weakening the
protein–DNA interactions [32, 33]. Although a system-
atic comparison of these approaches is still missing,
they have led to varying success and it has been ob-
served that different targets are cleaved with different
off-target propensity by SpCas9. Unfortunately, in the
absence of a sufficiently accurate prediction tool, the
off-target propensity of SpCas9 on a given target can
be determined only by time-consuming and laborious
genome-wide off-target analysis, apart from when ho-
mopolymeric and repetitive sequences are encoun-
tered, which have been already reported to be cleaved
with high off-target effects and hence could be easily
avoided. For the targeting of sequences in the bulk of
the genome our results take a step forward in over-
coming these difficulties.
Fig. 6 Transcription activation is not impaired compared to the WT when the nuclease variants are charged with altered sgRNAs. Transcription
activation of an EGFP inserted after the Prnp promoter, employing five targets in the promoter region. a Active nuclease variants programmed
with 15-nucleotide-long truncated MS2 aptamer-containing sgRNAs. b Dead nuclease variants programmed with 21-nucleotide-long MS2
aptamer-containing sgRNAs. Spacers used are shown as combs where green represents matching and red mismatching positions; lower case g
represents appended nucleotides to the 5′ end of the guide; numbering corresponds to the distance from the PAM. Bars correspond to averages
of n = 3 parallel samples; error bars represent the standard deviations
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The most important outcomes of the experiments re-
ported here are (i) the observed fidelity or activity and
target selectivity ranking among the increased fidelity
nucleases and (ii) a ranking of the cleavability of targets
without off-target effects by these nuclease variants.
These results may be understandable now, but before
this study it was not clear [32, 33] whether the muta-
tions in eSpCas9 or SpCas9-HF1, although aiming at
non-specific contacts, altered their sequence specificity,
i.e., if eSpCas9 and SpCas9-HF1 exhibit lower activities
on distinct sets of targets, a result which would not sup-
port the existence of the target-ranking discerned here.
It was also not clear whether SpCas9-HF1 had higher fi-
delity than eSpCas9 and whether off-target propensities
varied according to the target.
According to our findings, eSpCas9 possesses the low-
est target selectivity among the increased fidelity nucle-
ases examined here. It has activity comparable to that of
WT SpCas9 when employed with 20-nucleotide-long,
perfectly matching sgRNAs and because of its higher fi-
delity its routine use is preferable to using WT SpCas9
for practically all applications. We did not find a single
target for which WT SpCas9 shows higher specificity
(defined as on-target/off-target ratio) than eSpCas9. In
contrast, SpCas9-HF1 showed strongly decreased ac-
tivities for some targets (such as targets 6, 18, 19, and
21 in Fig. 3a and 27, 40, 45 and 50 in Additional file 1:
Figure S8a) in these experiments. Even though it ex-
hibits markedly higher specificity for several targets
(e.g., targets 2, 9, 14, and 16 in Fig. 4) than eSpCas9, it
may not be advisable to use it routinely for any targets
without pretesting. Kleinstiver et al. suggested that
SpCas9-HF1 cleaves only “atypical”, repetitive, or ho-
mopolymeric targets with substantial off-target pro-
pensity [33]. According to our experiments, some
typical targets that are not homopolymeric or repeti-
tive sequences are also cleaved with higher off-target
propensity by SpCas9-HF1. The proportion of such
targets exceeds 10% occurrence in our experiments.
Unfortunately, at present we are not able to predict
which targets would have a higher off-target propen-
sity, which limits the unrestricted use of SpCas9-HF1
for DNA modifications aimed at avoiding off-target ef-
fects. The HeF nucleases developed here exhibit
greatly increased fidelity and an accompanying in-
creased target selectivity/lower activity, a finding that
may not be surprising. However, we found it striking
that they exhibit this high fidelity specifically for those
targets for which SpCas9-HF1 fails to show improved
fidelity. This suggests that HeF variants will be very
useful complements to the already existing increased
fidelity nucleases in genome engineering applications,
perfectly fulfilling the anticipated role for which we
generated them.
Another interesting result is the finding that 5′ ex-
tending the sgRNAs with a single G nucleotide dimin-
ishes the activities of the increased fidelity SpCas9
variants. A 5′ GG dinucleotide extension of the sgRNA
has been reported to decrease the off-target cleavage
propensity of SpCas9 with certain targets [21]. Since the
5′ end of the sgRNAs protrudes relatively freely from
the known SpCas9–sgRNA structures [9] (Additional
file 1: Figure S11a, b), the mechanism by which the 5′
dinucleotide extension decreases off-target propensity
was not apparent and it was suggested that it may alter
the guide RNA’s stability, concentration, or secondary
structure [21]. More recently a structure of SpCas9 has
been published, which provides the most detailed pic-
ture of a cleavage-competent state of the SpCas9–
sgRNA complex [60]. According to this structure the 5′
end of the sgRNA is not only buried inside the protein,
but if extended it could only exit the protein’s structure
at a separate opening that is at some distance from the
target DNA strand and separated from it by parts of
the protein (Additional file 1: Figure S11c–e). Such a
structural arrangement would explain how a 5′ G ex-
tension may disturb the cleavage but not the binding of
SpCas9. It also makes it understandable how a matching
G extension that would lengthen the RNA:DNA hybrid
helix may diminish much more the cleavage activities of
SpCas9 than a mismatching G may, by causing larger dis-
tortions to the cleavage-competent structure.
The results of these studies also extend our knowledge
of the factors that influence on-target and off-target
cleavages of SpCas9 and its increased fidelity variants in
several respects. High fidelity nucleases exhibit strongly
reduced activities with truncated sgRNAs, leading to the
conclusion that they are likely to improve specificity by
a similar mechanism to that of decreasing the inter-
action energy of the protein–sgRNA complex or R-loop
stability [22, 23]. Our results may further complement
this picture. First, increased fidelity nuclease variants
show decreased activity with 5′ extended guides as well,
suggesting a similar mechanism of action between ex-
tending (or truncating) the guide and variants engi-
neered to have reduced non-sequence specific DNA
contacts. Second, this contention of similar mechanisms
is further strengthened by the correlations we found be-
tween the activity-reducing effect of appending a 5′ G to
the sgRNAs and of using imperfectly matching sgRNAs
for cleaving the same target sequences with an increased
fidelity nuclease (Additional file 1: Figure S7). Third,
these correlations also show that highly reduced off-
target effects vary according to the target, an effect that
we term “off-targetless cleavability ranking” and is also
apparent in Fig. 4a. Fourth, we show here that increased
fidelity nucleases using sgRNAs that are incapable of
cleaving the DNA are able to elicit transcription
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activation and bind DNA in vitro similarly to the WT
protein (Fig. 6; Additional file 1: Figure S10). Altogether
these observations suggest that these modifications,
truncating or extending the guide and reducing non-
sequence specific protein–DNA contacts, improve
SpCas9 fidelity by primarily affecting the catalytic activity
of the cleavage complex without much altering the target
binding of SpCas9.
The most simple interpretation of these data is one
similar to that originally proposed to explain the off-
target activity of engineered zinc finger proteins [23, 61,
62]. However, in the case of SpCas9, the specificity of its
cleavage activity is determined by the interaction energy
of its cleavage complex rather than by its binding. In this
scenario, the actual sequence of a target also contributes
to the energy of the cleavage complex. With high
energy-contributing targets, the cleavage complex may
possess enough excess energy to tolerate mismatches in
the target DNA:RNA hybrid helix. With low energy-
contributing targets the cleavage complex has no or has
less excess energy; thus, it is less prone to off-target
cleavage. Approaches such as employing various in-
creased fidelity nuclease variants and truncating or ex-
tending the sgRNAs decrease the energy of the cleavage
complex to different extents: in some cases retaining
considerable off-target propensity, or in other cases
abolishing even the on-target activity, whereas in opti-
mal cases eliminating most or all of the off-target while
retaining high on-target cleavage activity.
Consequently, our data point to the fruitlessness of
attempting to generate a “generally superior” SpCas9 nu-
clease variant with overall highest specificity. Rather, an
optimal nuclease variant needs to be identified for each
target; this knowledge is critical for achieving further
minimization of unwanted, off-target cleavage of the
genome. Our data suggest that the fidelity of the im-
proved nuclease variants might be further increased by
combining them with a nickase approach. However,
since the binding activity of these increased fidelity nu-
cleases does not seem to decrease for targets not being
cleaved by the given variant (Additional file 1: Figure S10),
a combination with a dSpCas9-FokI approach is less likely
to be rewarding.
Our results on the use of 5′ G extended sgRNAs
(Fig. 2) also offer an alternative solution for increasing
the fidelity of WT SpCas9 cleavage. Given the fact that
extending the sgRNA with a G nucleotide only modestly
decreases the activity of WT SpCas9 (10% on average;
Fig. 2), on the basis of the interpretations provided here,
we predict a considerably decreased off-target cleavage
with such targets. Furthermore, it is plausible to specu-
late that in contrast to the so called tru-sgRNAs [23], a
matching G extension may not generate new off-target
sites that are not detected using the same unmodified
sgRNA-WT SpCas9 complex. In addition, it is likely to
increase the fidelity of WT SpCas9 more than non-
matching 5′ G extensions. These two ideas need further
confirmation.
One of the biggest challenges in the field remains to
develop methods for the prediction of the ranking of the
targets and their matching to the optimal off-target min-
imizing strategy. Both the approaches we developed here
and unbiased genome-wide off-target analyses are exces-
sively laborious and time-consuming, and thus it is not
feasible to apply them to reveal targets’ cleavability rank-
ing for routine use of SpCas9. However, the ranking of
the increased fidelity nucleases observed here offers a
straightforward solution to this problem: a simple pre-
testing of the candidate target with eSpCas9, SpCas9-
HF1, and HeFm2SpCas9 would reveal which is the high-
est fidelity nuclease exhibiting sufficient activity for the
given application.
For the therapeutic usage of the SpCas9-based tech-
nology it is of paramount priority to reduce the possibil-
ities for incidental off-targets to a minimum, even below
the detection limit of the currently existing approaches
(<0.1% imposed by the current NGS technology). These
applications frequently involve the optimization of a pro-
cedure based on exploiting one or a few targets that are
at appropriate positions for their later routine use. The
rankings observed here among these nucleases and
among targets and the extremely high fidelity of these
increased fidelity nucleases on certain targets suggest
that, by careful matching of the nuclease to the target
being exploited, the off-target cleavage may be reduced
even further to the level of incidentally occurring off-
targets that are not detectable by the current methods.
These, in turn, would greatly reduce the whole genome
sequencing effort required to validate engineered cells
for clinical applications without unwanted genomic
alterations.
Conclusions
Increased fidelity nucleases can routinely only be used
with perfectly matching 20-nucleotide-long spacers. A 5′
G extension of the sgRNAs is especially detrimental for
increased fidelity nucleases if the appended G matches
the target diminishing their cleavage activity. A fidelity
and target selectivity ranking of the increased fidelity
SpCas9 nucleases and a cleavability ranking of targets
could be revealed here due to our special experimental
design: application of SpCas9 variants with significantly
different fidelities compared side by side on the same set
of targets using a number of imperfectly matching
sgRNAs. These experiments revealed that eSpCas9 has
lower fidelity than SpCas9-HF1; however, owing to its
low target selectivity it may be used instead of WT
SpCas9 for higher fidelity gene editing in most of
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applications. Interestingly, contrary to expectations, the
higher fidelity SpCas9-HF1 also exhibited considerable
off-target propensity not only on “atypical” but also on
“typical” targets that feature no homopolymeric or re-
petitive sequences. By combining the mutations of these
two increased fidelity nucleases, we generated HeFSp-
Cas9, a highly enhanced fidelity nuclease, that is a very
useful complement to SpCas9-HF1 by cleaving exactly
those targets with little to no off-target effects (with a
considerable on-target activity) for which SpCas9-HF1
presented lower fidelity. The observed ranking of the nu-
cleases offers straightforward means for finding the opti-
mal nuclease variant for efficient on-target and minimal
off-target modifications. Our approach also provides a
framework for the generation of new high-fidelity nucle-
ase variants with fidelity in between that of the existing
ones, as it is demonstrated here by the development of
HeFm2SpCas9. This approach allows “optimal” in-
creased fidelity nuclease variants to tailored to individual
targets, matching them to achieve accurate genome edit-
ing with minimal off-target effects.
Methods
Materials
Restriction enzymes, Klenow polymerase, T4 ligase,
Dulbecco’s modified Eagle medium (DMEM; Gibco),
fetal bovine serum (Gibco), Turbofect, TranscriptAid T7
High Yield Transcription Kit and penicillin/streptomycin
were purchased from Thermo Fischer Scientific, protease
inhibitor cocktail was purchased from Roche Diagnostics.
DNA oligonucleotides and GenElute HP Plasmid Mini-
prep kit used in plasmid purifications were acquired from
Sigma-Aldrich. Q5 High-Fidelity DNA Polymerase was
from New England Biolabs Inc. NucleoSpin Gel and PCR
Clean-up kit was purchased from Macherey-Nagel. All
plasmid constructs and PCR products were sequenced by
Microsynth AG.
Plasmid construction
Vectors were constructed using standard molecular biol-
ogy techniques including one-pot cloning method [63],
Escherichia coli DH5α-mediated DNA assembly method
[64], and Body Double cloning method [65]. For detailed
cloning and sequence information see Additional file 3.
sgRNA target sites and mismatching sgRNAs are avail-
able in Additional file 2. The sequences of all plasmid
constructs were confirmed by Sanger sequencing.
Plasmids acquired from the non-profit plasmid distri-
bution service Addgene (http://www.addgene.org/)
were the following: pX330-U6-Chimeric_BB-CBh-
hSpCas9 (Addgene #42230) [8], eSpCas9(1.1) (Addgene
#71814) [32], VP12 (Addgene #72247) [33], pX335-U6-
Chimeric_BB-CBh-hSpCas9n(D10A) (Addgene #42335)
[8], pET-dCas9-VP64-6xHis (#62935) [58], sgRNA(MS2)
cloning backbone (Plasmid #61424) [51], MS2-P65-
HSF1_GFP (Plasmid #61423) [51].
Plasmids developed by us and that are deposited at
Addgene are the following: pX330-Flag-wtSpCas9 (with-
out sgRNA; Addgene #92353), pX330-Flag-eSpCas9
(without sgRNA; Addgene #92354), pX330-Flag-SpCas9-
HF1 (without sgRNA; Addgene #92102), HeFSpCas9
(Addgene #92355), HeFm1SpCas9 (Addgene #92110),
HeFm2SpCas9 (Addgene #92111), pX330-HA-dSpCas9
(Addgene #92112), pX330-Flag-dSpCas9 (Addgene
#92113), pX330-Flag-deSpCas9 (Addgene #92114),
pX330-Flag-dSpCas9-HF1 (Addgene #92115), pX330-
Flag-dHeFSpCas9 (Addgene #92116), pET-deSpCas9-
VP64-6xHis (Addgene #92117), pET-dSpCas9-HF1-
VP64-6xHis (Addgene #92118), pET-dHeFSpCas9-VP64-
6xHis (Addgene #92119), pmCherry_gRNA (Addgene:
#80457), U6-sgRNA(MS2)_EF1a-MS2-P65-HSF1 (Addgene
#92120).
Cell culture and transfection
N2a (neuro-2a mouse neuroblastoma cells, ATCC, CCL-
131) cells, N2a.EGFP and HEK-293.EGFP cells (both cell
lines containing a single integrated copy of an EGFP cas-
sette driven by the Prnp promoter), and HeLa (ATCC,
CCL-2) cells were grown at 37 °C in a humidified atmos-
phere of 5% CO2 in high glucose DMEM supplemented
with 10% heat-inactivated fetal bovine serum, 4 mM L-
glutamine (Gibco), 100 units/ml penicillin and 100 μg/ml
streptomycin. N2a, N2a.EGFP, and HEK-293.EGFP cells
were plated one day prior to transfection on 48-well plates
at a density of approximately 30,000 cells (35,000 cells in
the case of HEK-293.EGFP). HeLa cells were plated one
day prior to transfection in 24-well plates at a density of
approximately 60,000 cells. Transfections were performed
with TurboFect transfection reagent according to the
manufacturer’s recommended protocol and as detailed
below for each corresponding assay performed. Transfec-
tions were performed in triplicate unless otherwise noted.
Flow cytometry
Flow cytometry analyses were carried out on Attune
Acoustic Focusing Cytometer (Applied Biosystems) or
on CytoFLEX Flow Cytometer (Beckman Coulter). For
data analysis Attune Cytometric Software v.2.1.0 and
CytExpert 2.0 were used. Viable single cells were gated
based on side and forward light scatter parameters and a
total of 5000–10,000 viable single cell events were ac-
quired in all experiments. Attune Acoustic Focusing
Cytometer parameters: the GFP fluorescence signal was
detected using the 488-nm diode laser for excitation and
the 530/30-nm filter for emission; the mCherry fluores-
cent signal was detected using the 488-nm diode laser
for excitation and a 640LP filter for emission. CytoFLEX
Flow Cytometer parameters: the GFP fluorescence signal
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was detected using the 488-nm diode laser for excitation
and the 525/40-nm filter for emission; the mCherry
fluorescent signal was detected using the 638-nm diode
laser for excitation and a 660/20-nm filter for emission.
EGFP disruption assay
N2a.EGFP and HEK-293.EGFP cells were co-transfected
with two types of plasmids: SpCas9 expression plasmid
(137 ng) and sgRNA and mCherry coding plasmid
(78–97 ng) using 1 μl TurboFect reagent per well in
48-well plates. Where indicated, less SpCas9 plasmid
variants were used and their amounts are completed to
137 ng by a mock plasmid with identical size. Trans-
fected cells were analysed ∼ 72 and ∼ 168 h post-
transfection by flow cytometry. Transfection efficacy
was calculated via mCherry-expressing cells mea-
sured ∼ 72 h post-transfection. EGFP-positive cells
were counted both ∼ 72 and ∼ 168 h post-transfection.
Background level of EGFP for each experiment was de-
termined using non-transfected cells and also two
types of control transfected population: (i) using co-
transfection of a mock plasmid (pmCherry_sgRNA)
and an active SpCas9 plasmid; or (ii) using co-
transfection of a dead SpCas9 expression plasmid and
a targeted sgRNA and mCherry coding plasmid.
Percentage of EGFP disruption in the case of
N2a.EGFP cells was calculated as follows. The measured
percentage of EGFP-positive cells for each sample was
subtracted from the total average obtained on the con-
trols and was weighted by its transfection efficiency fac-
tor. The transfection efficiency factor was obtained
utilizing the mCherry present in the samples: by measur-
ing the percentage of mCherry-positive cells in individual
samples and calculating their deviation from the average
percentage of mCherry-positive cells obtained on all the
transfected samples/wells as (Average mCherry – Sample
mCherry)/(Average mCherry). For each sample three par-
allels were processed and their values were averaged. The
errors associated with the final values were estimated by
taking into account the errors of each term, mCherry and
EGFP controls as well, using Gaussian error propagation
on the standard deviations. When data were further used
for ratio plotting, the errors were also processed further
by Gaussian propagation to yield the final represented
error bars. In the case of HEK-293.EGFP cells the
mCherry fluorescence was not used to normalize the data.
HR-mediated integration assay
Cells were co-transfected with three types of plasmids:
an expression plasmid for EGFP flanked by 1000-bp-
long homology arms to the Prnp gene (referred to as
Prnp.HA-EGFP plasmid; Tálas et al. [66]; 166 ng),
SpCas9 expressing plasmid (42 ng), and an sgRNA/
mCherry coding plasmid (42 ng), giving 250 ng total
plasmid DNA, using 1 μl TurboFect reagent per well on
48-well plates. Transfected cells were analyzed ∼ 72 h
and 12 days post-transfection by flow cytometry. Trans-
fection efficacy was calculated via mCherry-expressing
cells measured ∼ 72 h post-transfection. EGFP-positive
cells were counted 12 days post-transfection on three
parallels. Background level of EGFP was determined by
control co-transfection using dead SpCas9 expression
plasmid, Prnp.HA-GFP plasmid and a mouse Prnp site
1B targeting-sgRNA/mCherry coding plasmid. Values
obtained for each sample well were weighted to count
for their transfection efficiency utilizing the sample’s
mCherry fluorescence and the average mCherry fluores-
cence value obtained based on all transfected wells as
described in an EGFP disruption assay. The weighted
values of the samples were averaged for parallels and
corrected for the control average values. The error was
estimated by Gaussian error propagation of the errors
(standard deviation) associated with each term experi-
mentally determined that was used for calculation of the
value.
TIDE
The Tracking of Indels by DEcomposition (TIDE)
method [36] was applied for analyzing mutations and
determining their frequency in a cell population using
different sgRNAs and SpCas9 proteins.
N2a cells were co-transfected with 137 ng of SpCas9
expressing plasmid and 97 ng of sgRNA and mCherry
coding plasmid (250 ng total plasmid DNA) using 1 μl
TurboFect reagent per well on 48-well plates.
HeLa cells were co-transfected with 400 ng of SpCas9-
expressing plasmid and 600 ng of sgRNA/mCherry cod-
ing plasmid (1 μg total plasmid DNA) using 2 μl Turbo-
Fect reagent per well on 24-well plates.
Control samples were made for each different genomic
target site by co-transfecting a dead SpCas9 expression
plasmid and the targeted sgRNA and mCherry coding
plasmid.
Transfected cells were divided ∼ 72 h post-transfection
as follows: 20% of the cells were analyzed for transfec-
tion efficacy via mCherry fluorescence by flow cytometry
and from the rest of the cells genomic DNA was ex-
tracted by following the Gentra DNA Purification proto-
col (Gentra Puregen Handbook, Qiagen) from the mix
of the triplicates. From the isolated genomic DNA PCR
was conducted with Q5 High-Fidelity DNA Polymerase
(for PCR primer details, see Additional file 2). Genomic
PCR products were gel excised (in the case of experi-
ments shown in Additional file 1: Figure S1b) or directly
purified (in the case of experiments shown in Fig. 5c) via
NucleoSpin Gel and PCR Clean-up kit and were Sanger
sequenced. Indel efficiencies were analyzed using the
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TIDE webtool (https://tide.nki.nl/) by comparing Cas9-
treated and control samples.
Indel analysis by next-generation sequencing
Off-targets with low cleavage efficacy in the EGFP dis-
ruption assay together with their on-targets were exam-
ined via targeted resequencing. The genomic DNA was
extracted at ∼ 7 days post-transfection from the mix of
the triplicates by following the Gentra DNA Purification
protocol. PCR fragments for NGS analysis were gener-
ated in two-step PCR reactions. Briefly, first step PCR
primers (Additional file 2) contained both the PCR
handles for the second round amplification and the
target-specific sequence to amplify genomic regions of
interest. The second ten-cycle PCR step, the purification
(Ampure Bead clean up), the pooling, the gel excised
purification, and the 150-bp single-end sequencing on
an Illumina MiSeq instrument were performed by
Microsynth AG.
Western blotting
N2a.EGFP cells were cultured on a 48-well plate and
transfected as described above in the “EGFP disruption
assay” section. Three days post-transfection, eight paral-
lel samples corresponding to each type of Cas9 trans-
fected were washed with PBS, then trypsinized and
mixed, and were analyzed for transfection efficacy via
mCherry fluorescence level by using flow cytometry.
The cells from the mixtures were pelleted (at 200 rcf for
5 min at 4 °C). The pellet was resuspended in ice cold
Harlow buffer (50 mM Hepes pH 7.5; 0.2 mM EDTA;
10 mM NaF; 0.5% NP40; 250 mM NaCl; Proteinase
Inhibitor Cocktail 1:100; Calpain inhibitor 1:100; 1 mM
DTT) and lysed for 20–30 min. The cell lysates were
centrifuged at 19,000 rcf for 10 min. The supernatants
were transferred into new tubes and total protein con-
centration was measured by Bradford protein assay. Be-
fore SDS gel loading, samples were boiled in Protein
Loading Dye for 10 min at 95 °C. Proteins were sepa-
rated by SDS-PAGE using 7.5% polyacrylamide gels and
were transferred to PVDF membrane, using a wet blot-
ting system (Bio-Rad). Membranes were blocked by 5%
non-fat milk in Tris buffered saline with Tween20
(TBST; blocking buffer) for 2 h. Blots were incubated
overnight at 4 °C with primary antibodies [anti-FLAG
(F1804, Sigma) at 1:1000 dilution; anti-β-actin (A1978,
Sigma) at 1:4000 dilution in blocking buffer]. The next
day after washing steps in TBST the membranes were
incubated for 1 h with HRP-conjugated secondary anti-
mouse antibody 1:20,000 (715-035-151, Jackson Immu-
noResearch) in blocking buffer. The signal from detected
proteins was visualized by ECL (Pierce ECL Western
Blotting Substrate, Thermo Scientific) by CCD camera
(Bio-Rad ChemiDoc MP).
Transcriptional activation
N2a.EGFP cells were co-transfected with three types of
plasmids as follows: 91 ng of SpCas9-expressing plasmid,
83 ng of the mixture of 5 sgRNA coding plasmid, which
expresses MS2-p65-HFS1 fusion protein as well, and
75 ng of mCherry coding plasmid (pcDNA3-mCherry)
using 1 μl TurboFect reagent per well in 48-well plates.
Transfected cells were analyzed ∼ 72 h post-transfection.
The transfection efficacy was calculated via mCherry
fluorescence level. The relative upregulation was calcu-
lated from the median of the EGFP intensity. Back-
ground level of EGFP was determined using a negative
control for transfections: a mock plasmid ([MS2-p65-
HFS1_sgRNA(MS2)] without spacer sequence) co-
transfected with SpCas9 coding plasmid and with
mCherry coding plasmid. The medians obtained for
EGFP fluorescence were averaged between three
parallel samples and the error was estimated by
Gaussian error propagation of the component errors
(standard devitation) associated with the measured
variables.
In vitro transcription
sgRNAs were in vitro transcribed using TranscriptAid
T7 High Yield Transcription Kit and PCR-generated
double-stranded DNA templates carrying a T7 promoter
sequence. Primers used for the preparation of the DNA
templates are listed in Additional file 2. sgRNAs were
quality checked using 10% denaturing polyacrylamide
gels and ethidium bromide staining.
Protein purification
pET-dCas9-VP64-6xHis (#62935) was acquired from
Addgene and the other Cas9 variants (pET-deSpCas9-
VP64-6xHis, pET-dSpCas9-HF1-VP64-6xHis, pET-
dHeFSpCas9-VP64-6xHis) were subcloned by us (for
detailed cloning information and sequence information see
the “Plasmid construction” section and Additional file 3).
The resulting fusion constructs contained an N-terminal
hexahistidine (His6) tag.
The expression constructs of the dead Cas9 variants
were transformed into BL21 Rosetta 2 (DE3) cells and
were processed similarly, as follows. Cells were grown
in LB medium at 37 °C for 5 h and 10 ml of this cul-
ture was inoculated into 1 l of Terrific Broth growth
media and cells were grown at 37 °C to a final cell
density of 0.6 OD600 and then chilled to 18 °C. The
protein was expressed at 18 °C for 16 h following in-
duction with 0.2 mM IPTG. The protein was purified
by a combination of chromatographic steps using an
NGC Scout Medium-Pressure Chromatography Sys-
tem (Bio-Rad). Briefly, the cells were harvested and
resuspended in 30 ml of lysis buffer (40 mM Tris
pH 8.0, 500 mM NaCl, 20 mM imidazole, 1 mM
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TCEP) supplemented with protease inhibitor cocktail
(complete, EDTA-free) and were sonicated on ice.
The lysate was cleared by centrifugation at 18,000 rcf
for 40 min at 4 °C. The supernatant was bound in
batch to a 5 ml Mini Nuvia IMAC Ni-Charged col-
umn (Bio-Rad). The resin was washed extensively
with 40 mM Tris pH 8.0, 500 mM NaCl, 20 mM
imidazole, and the bound protein was eluted by
40 mM Tris pH 8.0, 250 mM imidazole, 150 mM
NaCl elution buffer. The protein was dialyzed 2 × 1 h
against 20 mM HEPES pH 7.5, 150 mM KCl, 1 mM
DTT, 1% glycerol. The dialyzed protein was purified
on a 3 × 1 ml Bio-Scale Mini Macro-Prep High S col-
umn (Bio-Rad), eluting with 1 M KCl, 20 mM HEPES
pH 7.5, 1 mM DTT. The protein was further purified
by size exclusion chromatography on a Superdex 200
16/60 column in 20 mM HEPES pH 7.5, 150 mM
KCl, and 1 mM DTT. The eluted protein was tested
on SDS-PAGE and Coomassie brilliant blue r-250
staining and was stored at −20 °C until use.
Electrophoretic mobility shift assay
Binding assays were performed in buffer containing
20 mM HEPES pH 7.5, 100 mM KCl, 5 mM MgCl2,
0.1 mg/ml heparin, and 1 mM TCEP in a total volume
of 20 μl. The sgRNA was supplied at two times the
molar amount of protein. The target DNA (40 nM)
was incubated with protein–sgRNA complex (160 nM;
or in the case of the serial dilution experiments with
160, 320, 640, and 1280 nM protein–sgRNA complex
concentrations, respectively) for 30 min at 37 °C.
Samples were resolved at 4 °C on an 8% native poly-
acrylamide gel containing 0.5× TBE and 10 mM
MgCl2. The gel was stained with ethidium bromide.
(For detailed information about sgRNAs and DNA tar-
gets see Additional file 2).
Statistics
Differences between samples were tested using Welch’s
one-way Anova with Games–Howell post hoc tests for
samples with unequal variances and/or sample size
(Figs. 2a, b, 3b, 5a; Additional file 1: Figures S2b, S3b,
S8b) and by one-way Anova with Tukey’s post-hoc test
for homoscedastic samples (Fig. 3b; Additional file 1:
Figures S1f and S2a, 2e). Homogeneity of variances was
tested by Levene’s test. Statistical tests were performed
using R version 3.4.1 (C: 2017 The R Foundation for
Statistical Computing) and packages FSA, Car, multcomp,
userfriendlyscience, dplyr, ggplot2. Test results are in
Additional file 4.
The investigators were not blinded to group assign-
ment and outcome assessment.
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